The impacts of biologic treatment on metabolic profiling in psoriasis
Sichun Deng
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorGuowei Zhou
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorXingyu Li
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorGuanxiong Zhang
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorKun Hu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorYan Lu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorJiashuai Li
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorYijie Liu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorGuo Zhou
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorMi Zhang
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorCorresponding Author
Junchen Chen
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Correspondence
Yehong Kuang, Hong Liu and Junchen Chen, The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Email: [email protected]; [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Hong Liu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Correspondence
Yehong Kuang, Hong Liu and Junchen Chen, The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Email: [email protected]; [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Yehong Kuang
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Correspondence
Yehong Kuang, Hong Liu and Junchen Chen, The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Email: [email protected]; [email protected] and [email protected]
Search for more papers by this authorSichun Deng
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorGuowei Zhou
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorXingyu Li
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorGuanxiong Zhang
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorKun Hu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorYan Lu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorJiashuai Li
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorYijie Liu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorGuo Zhou
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorMi Zhang
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Search for more papers by this authorCorresponding Author
Junchen Chen
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Correspondence
Yehong Kuang, Hong Liu and Junchen Chen, The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Email: [email protected]; [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Hong Liu
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Correspondence
Yehong Kuang, Hong Liu and Junchen Chen, The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Email: [email protected]; [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Yehong Kuang
The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China
Furong Laboratory, Changsha, Hunan, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China
Correspondence
Yehong Kuang, Hong Liu and Junchen Chen, The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Email: [email protected]; [email protected] and [email protected]
Search for more papers by this authorSichun Deng, Guowei Zhou and Xingyu Li have contributed equally to this work.
Abstract
Psoriasis is an immune-mediated inflammatory disease commonly accompanied by various metabolic disorders. It is widely known that biologics could affect the metabolic status and comorbidities in psoriasis patients, however, the effects of biologics on metabolism in psoriasis patients remain poorly understood. The aim of this study was to elucidate the characteristic changes of metabolic profiling in psoriasis vulgaris (PsV) patients before and after applying biologics. Plasma samples were collected from a retrospective cohort of 43 PsV patients. Non-targeted metabolomics analyses were performed using liquid chromatography-mass spectrometry (LC–MS) to compare the metabolic profiles before and after applying adalimumab (ADA) or ixekizumab (IXE) for 4 weeks. Additionally, correlation analyses were conducted to investigate the associations between metabolite expression levels and clinical characteristics. The biologics significantly affected the metabolic profiles of PsV patients especially in glycerophospholipids (GPs). First, phosphatidylcholine (PC), unsaturated lysophosphatidylcholine (LPC), unsaturated lysophosphatidic acid (LPA) and unsaturated lysophosphatidylethanolamine (LPE) were significantly up-regulated, whereas phosphatidylethanolamine (PE), saturated LPC, saturated LPA and saturated LPE were predominantly down-regulated after biologic treatment. What is more, the changes in PE and LPA were mainly observed after applying IXE instead of ADA. Second, we also found GPs including PC, unsaturated LPC, unsaturated LPA and unsaturated LPE were primarily negatively correlated with disease severity, whereas, PE, saturated LPC, saturated LPA and saturated LPE displayed inverse correlations. Biologics could affect GP metabolism and facilitate the transition of metabolic status from a pro-inflammatory to an anti-inflammatory phenotype in PsV patients.
CONFLICT OF INTEREST STATEMENT
All authors have declared no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| exd15011-sup-0001-FigureS1.pdfPDF document, 857.2 KB |
Figure S1. Permutation test results of orthogonal PLS-DA from psoriasis patient cohorts. |
| exd15011-sup-0002-TableS1.xlsxExcel 2007 spreadsheet , 11.5 KB |
Table S1. Glycerophospholipids changed by ADA. |
| exd15011-sup-0003-TableS2.xlsxExcel 2007 spreadsheet , 13.6 KB |
Table S2. Glycerophospholipids changed by IXE. |
| exd15011-sup-0004-TableS3.xlsxExcel 2007 spreadsheet , 25.1 KB |
Table S3. Glycerophospholipids correlated with disease severity. |
| exd15011-sup-0005-TableS4.xlsxExcel 2007 spreadsheet , 10.4 KB |
Table S4. The comparison of significantly regulated metabolites between ADA and IXE treatment group. |
| exd15011-sup-0006-TableS5.xlsxExcel 2007 spreadsheet , 9.1 KB |
Table S5. The comparison of significantly regulated pathway between ADA and IXE treatment group. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275): 754-766.
- 2Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008; 20(4): 416-422.
- 3Hu Y, Zhu Y, Lian N, Chen M, Bartke A, Yuan R. Metabolic syndrome and skin diseases. Front Endocrinol (Lausanne). 2019; 10: 788.
- 4Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115(4): 721-728.
- 5Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(6): 797-806.
- 6Zeng C, Wen B, Hou G, et al. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis. Gigascience. 2017; 6(10): 1-11.
- 7Xiong Q, Zhong D, Li Q, et al. LC-MS metabolomics reveal skin metabolic signature of psoriasis vulgaris. Exp Dermatol. 2023; 32: 889-899.
- 8Chen C, Hou G, Zeng C, Ren Y, Chen X, Peng C. Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis. Theranostics. 2021; 11(2): 754-767.
- 9Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018; 45(3): 279-286.
- 10Camela E, Ocampo-Garza SS, Cinelli E, Villani A, Fabbrocini G, Megna M. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatol Ther. 2021; 34(2):e14857.
- 11Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PloS One. 2018; 13(5):e0195123.
- 12Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic Core: results from a prospective, observational study. Circ Cardiovasc Imaging. 2020; 13(9):e011199.
- 13Kamleh MA, Snowden SG, Grapov D, et al. LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment. J Proteome Res. 2015; 14(1): 557-566.
- 14Ridgway ND. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit Rev Biochem Mol Biol. 2013; 48(1): 20-38.
- 15Eros G, Ibrahim S, Siebert N, Boros M, Vollmar B. Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis. Arthritis Res Ther. 2009; 11(2): R43.
- 16Hartmann P, Szabó A, Eros G, et al. Anti-inflammatory effects of phosphatidylcholine in neutrophil leukocyte-dependent acute arthritis in rats. Eur J Pharmacol. 2009; 622(1–3): 58-64.
- 17Jung YY, Nam Y, Park YS, et al. Protective effect of phosphatidylcholine on lipopolysaccharide-induced acute inflammation in multiple organ injury. Korean J Physiol Pharmacol. 2013; 17(3): 209-216.
- 18Liu P, Zhu W, Chen C, et al. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 2020; 247:117443.
- 19Liu P, Zhou Y, Chen C, et al. Lysophosphatidylcholine facilitates the pathogenesis of psoriasis through activating keratinocytes and T cells differentiation via glycolysis. J Eur Acad Dermatol Venereol. 2023; 37: 1344-1360.
- 20Murugesan G, Sandhya Rani MR, Gerber CE, et al. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J Mol Cell Cardiol. 2003; 35(11): 1375-1384.
- 21Bach G, Perrin-Cocon L, Gerossier E, et al. Single lysophosphatidylcholine components exhibit adjuvant activities in vitro and in vivo. Clin Vaccine Immunol. 2010; 17(3): 429-438.
- 22Hung ND, Sok DE, Kim MR. Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine. Inflamm Res. 2012; 61(5): 473-483.
- 23Knuplez E, Sturm EM, Marsche G. Emerging role of phospholipase-derived cleavage products in regulating eosinophil activity: focus on lysophospholipids, polyunsaturated fatty acids and eicosanoids. Int J Mol Sci. 2021; 22(9): 4356.
- 24Lei L, Yan B, Liu P, et al. Lysophosphatidic acid mediates the pathogenesis of psoriasis by activating keratinocytes through LPAR5. Signal Transduct Target Ther. 2021; 6(1): 19.
- 25Paolino G, Buratta S, Mercuri SR, et al. Lipidic profile changes in exosomes and microvesicles derived from plasma of monoclonal antibody-treated psoriatic patients. Front Cell Dev Biol. 2022; 10:923769.
- 26Bae M, Cassilly CD, Liu X, et al. Akkermansia muciniphila phospholipid induces homeostatic immune responses. Nature. 2022; 608(7921): 168-173.
- 27Uchida Y, Park K. Ceramides in skin health and disease: an update. Am J Clin Dermatol. 2021; 22(6): 853-866.
- 28Myśliwiec H, Baran A, Harasim-Symbor E, et al. Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. Arch Dermatol Res. 2017; 309(2): 79-86.
- 29Li Q, Fang H, Dang E, Wang G. The role of ceramides in skin homeostasis and inflammatory skin diseases. J Dermatol Sci. 2020; 97(1): 2-8.
- 30Nakajima K, Terao M, Takaishi M, et al. Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. J Invest Dermatol. 2013; 133(11): 2555-2565.
- 31Taniguchi M, Okazaki T. Role of ceramide/sphingomyelin (SM) balance regulated through "SM cycle" in cancer. Cell Signal. 2021; 87:110119.
- 32Hailemariam TK, Huan C, Liu J, et al. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol. 2008; 28(8): 1519-1526.
- 33Jin ZX, Huang CR, Dong L, et al. Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells. Int Immunol. 2008; 20(11): 1427-1437.
- 34Melum E, Jiang X, Baker KD, et al. Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. Nat Immunol. 2019; 20(12): 1644-1655.
- 35Yore MM, Syed I, Moraes-Vieira PM, et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell. 2014; 159(2): 318-332.
- 36Kuda O, Brezinova M, Rombaldova M, et al. Docosahexaenoic acid-derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties. Diabetes. 2016; 65(9): 2580-2590.
- 37Lee J, Moraes-Vieira PM, Castoldi A, et al. Branched fatty acid esters of hydroxy fatty acids (FAHFAs) protect against colitis by regulating gut innate and adaptive immune responses. J Biol Chem. 2016; 291(42): 22207-22217.
- 38Kolar MJ, Konduri S, Chang T, et al. Linoleic acid esters of hydroxy linoleic acids are anti-inflammatory lipids found in plants and mammals. J Biol Chem. 2019; 294(27): 10698-10707.
- 39Wang N, Yang L, Shang L, et al. Altered fecal metabolomics and potential biomarkers of psoriatic arthritis differing from rheumatoid arthritis. Front Immunol. 2022; 13:812996.
- 40Wei Y, Liu C, Li L. Geniposide improves bleomycin-induced pulmonary fibrosis by inhibiting NLRP3 inflammasome activation and modulating metabolism. J Funct Foods. 2023; 104:105503.
- 41Harmon CS, Phizackerley PJ. Glycogen metabolism in psoriatic epidermis and in regenerating epidermis. Clin Sci (Lond). 1984; 67(3): 291-298.
- 42Ma J, Wei K, Liu J, et al. Glycogen metabolism regulates macrophage-mediated acute inflammatory responses. Nat Commun. 2020; 11(1): 1769.
- 43Yu W, Wang Z, Zhang K, et al. One-carbon metabolism supports S-adenosylmethionine and histone methylation to drive inflammatory macrophages. Mol Cell. 2019; 75(6): 1147-1160.e1145.
- 44Hu X, Qi C, Feng F, et al. Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - Smilax glabra Roxb herb pair for the treatment of psoriasis. Phytomedicine. 2022; 105:154384.
- 45Li L, Chuan-Jian L, Ling H, et al. Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry. Oncotarget. 2017; 8(56): 95931-95944.
- 46Peng L, Chen L, Wan J, Liu W, Lou S, Shen Z. Single-cell transcriptomic landscape of immunometabolism reveals intervention candidates of ascorbate and aldarate metabolism, fatty-acid degradation and PUFA metabolism of T-cell subsets in healthy controls, psoriasis and psoriatic arthritis. Front Immunol. 2023; 14:1179877.
Citing Literature
